GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Document type
Publisher
Years
  • 1
    facet.materialart.
    Unknown
    Elsevier
    In: Lancet
    Publication Date: 2012-08-28
    Description: Publication year: 2012 Source: The Lancet Robert A Byrne, Adnan Kastrati, Jörg Hausleiter
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Publication Date: 2012-08-28
    Description: Publication year: 2012 Source: The Lancet Edoardo Camenzind, William Wijns, Laura Mauri, Volkhard Kurowski, Keyur Parikh, Runlin Gao, Christoph Bode, John P Greenwood, Eric Boersma, Pascal Vranckx, Eugene McFadden, Patrick W Serruys, William W O'Neil, Brenda Jorissen, Frank Van Leeuwen, Ph Gabriel Steg Background We sought to compare the long-term safety of two devices with different antiproliferative properties: the Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, Inc) and the Cypher sirolimus-eluting stent (C-SES; Cordis, Johnson & Johnson) in a broad group of patients and lesions. Methods Between May 21, 2007 and Dec 22, 2008, we recruited 8791 patients from 36 recruiting countries to participate in this open-label, multicentre, randomised, superiority trial. Eligible patients were those aged 18 years or older undergoing elective, unplanned, or emergency procedures in native coronary arteries. Patients were randomly assigned to either receive E-ZES and C-SES (ratio 1:1). Randomisation was stratified per centre with varying block sizes of four, six, or eight patients, and concealed with a central telephone-based or web-based allocation service. The primary outcome was definite or probable stent thrombosis at 3 years and was analysed by intention to treat. Patients and investigators were aware of treatment assignment. This trial is registered with ClinicalTrials.gov , number NCT00476957 . Findings PROTECT randomised 8791 patients, of whom 8709 provided consent to participate and were eligible: 4357 were allocated to the E-ZES group and 4352 patients to the C-SES group. At 3 years, rates of definite or probable stent thrombosis did not differ between groups (1·4% for E-ZES [predicted: 1·5%] vs 1·8% [predicted: 2·5%] for C-SES; hazard ratio [HR] 0·81, 95% CI 0·58–1·14, p=0·22). Dual antiplatelet therapy was used in 8402 (96%) patients at discharge, 7456 (88%) at 1 year, 3041 (37%) at 2 years, and 2364 (30%) at 3 years. Interpretation No evidence of superiority of E-ZES compared with C-SES in definite or probable stent thrombosis rates was noted at 3 years. Time analysis suggests a difference in definite or probable stent thrombosis between groups is emerging over time, and a longer follow-up is therefore needed given the clinical relevance of stent thrombosis. Funding Medtronic, Inc.
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    facet.materialart.
    Unknown
    Elsevier
    In: Lancet
    Publication Date: 2012-08-16
    Description: Publication year: 2012 Source: The Lancet Mark Boyd, Lerato Mohapi
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Publication Date: 2012-08-16
    Description: Publication year: 2012 Source: The Lancet Lara Fairall, Max O Bachmann, Carl Lombard, Venessa Timmerman, Kerry Uebel, Merrick Zwarenstein, Andrew Boulle, Daniella Georgeu, Christopher J Colvin, Simon Lewin, Gill Faris, Ruth Cornick, Beverly Draper, Mvula Tshabalala, Eduan Kotze, Cloete van Vuuren, Dewald Steyn, Ronald Chapman, Eric Bateman Background Robust evidence of the effectiveness of task shifting of antiretroviral therapy (ART) from doctors to other health workers is scarce. We aimed to assess the effects on mortality, viral suppression, and other health outcomes and quality indicators of the Streamlining Tasks and Roles to Expand Treatment and Care for HIV (STRETCH) programme, which provides educational outreach training of nurses to initiate and represcribe ART, and to decentralise care. Methods We undertook a pragmatic, parallel, cluster-randomised trial in South Africa between Jan 28, 2008, and June 30, 2010. We randomly assigned 31 primary-care ART clinics to implement the STRETCH programme (intervention group) or to continue with standard care (control group). The ratio of randomisation depended on how many clinics were in each of nine strata. Two cohorts were enrolled: eligible patients in cohort 1 were adults (aged ≥16 years) with CD4 counts of 350 cells per μL or less who were not receiving ART; those in cohort 2 were adults who had already received ART for at least 6 months and were being treated at enrolment. The primary outcome in cohort 1 was time to death (superiority analysis). The primary outcome in cohort 2 was the proportion with undetectable viral loads (〈400 copies per mL) 12 months after enrolment (equivalence analysis, prespecified difference 〈6%). Patients and clinicians could not be masked to group assignment. The interim analysis was blind, but data analysts were not masked after the database was locked for final analysis. Analyses were done by intention to treat. This trial is registered, number ISRCTN46836853. Findings 5390 patients in cohort 1 and 3029 in cohort 2 were in the intervention group, and 3862 in cohort 1 and 3202 in cohort 2 were in the control group. Median follow-up was 16·3 months (IQR 12·2–18·0) in cohort 1 and 18·0 months (18·0–18·0) in cohort 2. In cohort 1, 997 (20%) of 4943 patients analysed in the intervention group and 747 (19%) of 3862 in the control group with known vital status at the end of the trial had died. Time to death did not differ (hazard ratio [HR] 0·94, 95% CI 0·76–1·15). In a preplanned subgroup analysis of patients with baseline CD4 counts of 201–350 cells per μL, mortality was slightly lower in the intervention group than in the control group (0·73, 0·54–1.00; p=0·052), but it did not differ between groups in patients with baseline CD4 of 200 cells per μL or less (0·94, 0·76–1·15; p=0·577). In cohort 2, viral load suppression 12 months after enrolment was equivalent in intervention (2156 [71%] of 3029 patients) and control groups (2230 [70%] of 3202; risk difference 1·1%, 95% CI −2·4 to 4·6). Interpretation Expansion of primary-care nurses' roles to include ART initiation and represcription can be done safely, and improve health outcomes and quality of care, but might not reduce time to ART or mortality. Funding UK Medical Research Council, Development Cooperation Ireland, and Canadian International Development Agency.
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    facet.materialart.
    Unknown
    Elsevier
    In: Lancet
    Publication Date: 2012-09-15
    Description: Publication year: 2012 Source: The Lancet, Volume 380, Issue 9846
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    facet.materialart.
    Unknown
    Elsevier
    In: Lancet
    Publication Date: 2012-09-15
    Description: Publication year: 2012 Source: The Lancet, Volume 380, Issue 9846 The Lancet
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    facet.materialart.
    Unknown
    Elsevier
    In: Lancet
    Publication Date: 2012-09-15
    Description: Publication year: 2012 Source: The Lancet, Volume 380, Issue 9846 The Lancet
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    facet.materialart.
    Unknown
    Elsevier
    In: Lancet
    Publication Date: 2012-09-15
    Description: Publication year: 2012 Source: The Lancet, Volume 380, Issue 9846 The Lancet
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    facet.materialart.
    Unknown
    Elsevier
    In: Lancet
    Publication Date: 2012-09-15
    Description: Publication year: 2012 Source: The Lancet, Volume 380, Issue 9846 Richard Horton
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    facet.materialart.
    Unknown
    Elsevier
    In: Lancet
    Publication Date: 2012-09-15
    Description: Publication year: 2012 Source: The Lancet, Volume 380, Issue 9846 Susan Jaffe
    Print ISSN: 0140-6736
    Electronic ISSN: 1474-547X
    Topics: Medicine
    Published by Elsevier
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...